First introduced in the Harvard Business Review in 2015, the Digital Evolution Index aims to trace the emergence of a ‘digital planet’ as technology displaces traditional interactions.
Recently given its first update, the Index analyses the state and rate of digital evolution across 60 countries, placing them into one of four zones. Read the rest of this entry »
SoundCloud staff reductions cut deep, Twitter strikes live-streaming deal with Live Nation, Pandora slims down its operations, internet music pioneer eMusic relaunches and Spotify defends itself from ‘fake artist’ accusations.
SoundCloud has cut 40% of its staff in a defensive move to protect its independence within an increasingly tough online music market. The decision comes despite doubling its revenue in the last 12 months, but co-founder Alex Ljung said that, alongside the cost-cutting, further growth is needed from its advertising and subscription revenue streams. Less than a week after that announcement Ljung was forced to put out a statement saying ‘SoundCloud is here to stay’. Read the rest of this entry »
It was a bumper issue of PME this month as we encompassed creativity, communications and consumerism, and tackled different strands of how pharma looks to reach and engage with its stakeholders.
On an industry level the German pharma market looks set for stable, if not strong, growth over the next four years, but it’s clearly anyone’s guess what will happen over that timeframe to the UK’s political landscape, and how that will in turn affect the industry.
What we can say with certainty is that European regulators aren’t waiting for the region’s politicians to thrash out a deal on the post-Brexit landscape. Instead the last month has seen concrete developments in the future shape of the regulatory environment, with a set of guidance now available, and – more recently – a delay to deciding the new location of the EMA. Read the rest of this entry »
Stranger things have been said by politicians, particularly recently, but I can’t have been the only person surprised by Greg Clark’s turn at this year’s ABPI annual conference.
Asked about the EMA Clark, the UK government’s spokesperson for business, energy and industrial strategy, told the UK pharma gathering he wanted “as many [European] institutions here as possible”, adding: “I would like the EMA to continue to be within the UK.”
Meanwhile, in the real world, the temperature is certainly rising on the issue of where Europe’s regulatory authority will be located, with ‘not in the UK’ seemingly the only certainty at the moment. A decision from the EU’s heads of government is expected in the Autumn, and Copenhagen, Barcelona, Dublin and Lisbon are among those stepping up their public campaigns to host the EMA. Read the rest of this entry »
In this digital music roundup – the first in a possible series: Spotify’s paywall, the US streaming market, Samsung and Google Play Music, Neil Young’s new streaming service Xstream and two augmented reality apps from Gorillaz (pictured above)
Spotify will allow labels to put new albums behind a two-week ‘paywall’, during which time they will only be available to the streaming service’s paying users. It concluded separate deals with digital rights agency Merlin, which negotiates on behalf of thousands of indies – including Sub Pop, Epitaph and Domino, and Universal Music Group (UMG). The flexible release policy also provides “unprecedented access to data, creating the foundation for new tools for artists and labels to expand, engage and build deeper connections with their fans”. Read the rest of this entry »
The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.
Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.
Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »